State-of-the-Art Research on Multiple Myeloma Progression
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 570
Special Issue Editor
Interests: plasma cell disorders; multiple myeloma; amyloidosis; plasma cell leukemia; CAR-T
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Multiple myeloma is a type of blood cancer that occurs when malignant plasma cells accumulate in the bone marrow. In recent years, science has made significant progress in understanding the molecular pathways involved in myeloma development and developing new drugs to treat the disease.
One crucial area of research has been the identification of genetic mutations and alterations that contribute to the development of myeloma. In addition, by studying the genomic landscape of myeloma, researchers have discovered new targets for drug development, such as inhibitors of the oncogene MYC, MDM2, IRF4, PERK, and others.
Another area of focus has been the development of immunotherapies, which harness the immune system's power to fight cancer. One promising approach has been the use of chimeric antigen receptor (CAR) T-cells or chimeric NK-cells therapy, which involves genetically engineering a donor's or patient's immune cells to recognize and attack myeloma cells and off-the-shelf bispecific T-cell engagers against multiple targets such as BCMA, GPRC5D, FcRH5, the cluster of differentiation (CD)1d and CD47, among others. In addition, the T-cell engager's underdevelopment could target multiple targets simultaneously.
Bench-to-bedside development is a vital process that enables the development of new therapies for myeloma, leading to improved patient outcomes and survival. The current state-of-the-art therapies in myeloma include immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, T-cell engagers, CAR-T cell therapies, and XPO-1 inhibitors.
The recent advances in myeloma research and drug development offer hope for improved outcomes for patients with this challenging disease.
Dr. Shebli Atrash
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- novel targets
- novel therapies
- molecular therapy
- immunotherapy
